Cancer immunotherapy has changed how researchers approach treatment development. Instead of targeting tumour cells alone, many newer therapies are designed to activate, redirect, or strengthen the patient’s immune response. This creates an important challenge during preclinical research because standard laboratory mice do not fully reproduce the behaviour of human immune cells.
PBMC humanized mice help address this gap by introducing human peripheral blood mononuclear cells into immunodeficient mice. The resulting model allows researchers to observe how human immune cells interact with tumours and respond to experimental treatments in a living biological system.
What Makes a Mouse Model “Humanized”?
A humanized mouse is an immunodeficient laboratory mouse that has been engrafted with human cells or tissues. Because the animal’s own immune system is severely weakened, transplanted human immune cells can survive and function for a limited period.
PBMC-based models use immune cells isolated from human blood. These cells include:
- T lymphocytes
- B lymphocytes
- Natural killer cells
- Monocytes
- Dendritic cell precursors
After transplantation, human T cells usually become the dominant immune population. This makes the model particularly useful for therapies that depend on T-cell activation, immune checkpoint signalling, or direct immune-cell targeting.
How PBMC Humanized Models Are Created
The process begins with the collection of blood from a qualified human donor. PBMCs are separated from other blood components and evaluated for viability, immune-cell composition, and suitability for engraftment.
The selected cells are then introduced into an immunodeficient mouse, commonly through intravenous or intraperitoneal injection. Researchers monitor blood samples to determine whether human immune cells have successfully established themselves in the animal.
A tumour may be implanted before or after immune-cell engraftment, depending on the experimental design. Researchers can use established cancer cell lines, patient-derived tumour material, or other xenograft systems.
A typical workflow includes:
- Donor screening and PBMC isolation
- Human immune-cell engraftment
- Confirmation of immune reconstitution
- Tumour implantation
- Treatment administration
- Immune and tumour-response analysis
This relatively direct workflow is one reason PBMC models are widely used for short-term immuno-oncology studies.
Why Rapid Immune Reconstitution Matters
Human immune cells can establish themselves relatively quickly in PBMC-engrafted mice. Some model systems report measurable T-cell reconstitution within one to two weeks, allowing treatment studies to begin sooner than models created with human hematopoietic stem cells.
The faster setup can benefit early-stage drug development. Researchers may need to compare several therapeutic candidates before selecting the most promising option for longer and more expensive studies.
PBMC models can therefore support:
- Initial candidate screening
- Proof-of-concept experiments
- Dose comparison studies
- Combination therapy evaluation
- Early biomarker investigation
Their relatively short experimental timeline can also help research teams make decisions before advancing a programme into more complex models.
Testing New Forms of Cancer Immunotherapy
Many immunotherapies depend on interactions that are specific to human immune receptors and signalling pathways. Conventional mouse models may not accurately represent these interactions because mouse and human immune systems differ in receptor expression, cytokine biology, and cellular responses.
PBMC humanized mice give researchers access to functioning human immune cells within an in vivo setting. This makes them valuable for evaluating therapies such as:
- Immune checkpoint inhibitors
- T-cell-engaging antibodies
- Bispecific antibodies
- CAR-T cell therapies
- Monoclonal antibodies
- Antibody-drug conjugates
- Immune-modulating combination therapies
For example, a researcher studying a checkpoint inhibitor can assess whether the treatment increases human T-cell activation, slows tumour growth, or changes immune-cell infiltration within the tumour.
These models do not predict clinical outcomes with certainty. However, they can reveal biological activity that may be missed in systems lacking human immune components.
Measuring More Than Tumour Size
Tumour volume is an important endpoint, but it provides only part of the picture. A treatment may alter immune activity before producing a measurable change in tumour growth.
Researchers can combine tumour measurements with immune profiling to understand how a therapy works. Common endpoints include:
- Human T-cell expansion
- CD4 and CD8 T-cell ratios
- Immune-cell infiltration
- Cytokine and chemokine levels
- T-cell activation markers
- Effector and memory T-cell populations
- Tumour-cell death
- Treatment-related toxicity
Flow cytometry can measure immune-cell populations in blood, spleen, and tumour tissue. Immunohistochemistry can show where immune cells are located within the tumour microenvironment. Cytokine analysis can reveal whether treatment is stimulating or suppressing specific inflammatory pathways.
Combining these measurements provides a more detailed view of treatment response than tumour size alone.
Studying Cytokine Release and Immune Safety
Powerful immune therapies can produce strong inflammatory responses. One potential complication is cytokine release syndrome, which occurs when activated immune cells release high levels of signalling molecules into the bloodstream.
PBMC models can help researchers examine cytokine changes after treatment and identify therapies that cause excessive immune activation. This is particularly relevant for T-cell engagers, CAR-T therapies, and other treatments designed to stimulate rapid immune responses.
Researchers may monitor cytokines such as:
- Interleukin-6
- Interferon-gamma
- Tumour necrosis factor
- Interleukin-2
- Interleukin-10
These results can support early safety assessment, although they should not be interpreted as a complete prediction of human toxicity. Cytokine biology is complex, and no single animal model reproduces every aspect of a patient’s response.
Donor Variation Can Be Both Useful and Challenging
PBMCs retain characteristics from the individual who donated them. Two donors may produce different levels of immune-cell engraftment or respond differently to the same treatment.
This variation creates a challenge for reproducibility. A therapy may appear effective with cells from one donor but show a weaker response with another. Differences in human leukocyte antigen type, immune-cell composition, previous antigen exposure, and T-cell activity can all influence results.
At the same time, donor variation can provide valuable information. Testing several donors may reveal whether a treatment works broadly or depends on a particular immune profile.
Careful donor screening is therefore essential. Researchers should consider:
- Baseline immune-cell composition
- T-cell viability and activity
- Engraftment consistency
- HLA characteristics
- Previous donor performance
- Propensity to produce graft-versus-host disease
Using qualified donor pools and clearly documenting donor characteristics can improve the interpretation of study results.
Understanding the Main Limitations
The major limitation of the PBMC model is xenogeneic graft-versus-host disease. Human T cells eventually recognise mouse tissues as foreign and begin attacking them. This can cause weight loss, inflammation, tissue injury, and declining animal health.
The timing varies according to the mouse strain, donor, number of transplanted cells, injection method, and conditioning procedure. In many studies, significant disease develops within several weeks, creating a limited window for treatment evaluation.
Other limitations include:
- Strong T-cell dominance
- Limited long-term B-cell function
- Weak or inconsistent myeloid-cell engraftment
- Donor-to-donor variability
- Incomplete human cytokine signalling
- Differences between mouse and human tissue environments
These limitations do not make the model unsuitable. They mean researchers must choose it for questions that match its biological strengths.
Designing More Reliable Studies
A well-designed study should account for the model’s short timeline and donor-dependent behaviour from the beginning.
Researchers can improve reliability by screening PBMC donors before the main experiment, confirming human immune-cell engraftment, and defining treatment schedules before graft-versus-host symptoms become substantial.
Appropriate controls are equally important. A study may include untreated animals, tumour-only animals, humanized animals without therapy, and groups receiving an established reference treatment.
Other useful practices include:
- Randomising animals between treatment groups
- Balancing donors across experimental groups
- Monitoring weight and clinical condition
- Establishing predefined humane endpoints
- Measuring both tumour and immune responses
- Reporting the mouse strain and engraftment method
- Confirming target expression before treatment
These steps help distinguish a genuine treatment effect from variation caused by the model itself.
Looking Ahead
No preclinical system can reproduce the complete complexity of human cancer and immunity. However, PBMC humanized mice provide a practical way to study human T-cell responses within a living tumour environment.
Their rapid establishment makes them particularly useful for short-term immunotherapy evaluation, candidate prioritisation, and mechanistic research. Their limitations, especially graft-versus-host disease and incomplete immune-cell representation, require careful experimental planning.
Researchers are now developing next-generation host strains with altered immune recognition, improved human cytokine support, and longer study windows. These advances may allow PBMC-based models to represent a wider range of immune responses while reducing complications.
Used alongside cell assays, organoids, stem-cell humanized models, and clinical data, PBMC models can contribute to stronger preclinical evidence. Their greatest value lies not in replacing other research systems, but in helping scientists ask more relevant questions about how human immune cells respond to emerging cancer therapies.
Disclaimer: The information provided in this article is for general informational and educational purposes only. It does not constitute professional scientific, medical, or research advice. Preclinical models have inherent limitations and do not fully replicate human biology. The description of PBMC humanized mouse models, workflows, and outcomes is illustrative; results may vary based on experimental conditions. Readers should consult qualified research professionals and follow applicable ethical and regulatory guidelines. The author and publisher disclaim all liability for any research decisions, experimental failures, or misinterpretations arising from reliance on this content. This article does not guarantee specific experimental outcomes.
Unlock the power of knowledge—explore curated ease that truly fits the rhythm of your life.
